CytomX Therapeutics Inc CTMX:NASDAQ

Last Price$1.65NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/18/22

Today's Change+0.02(1.23%)
Bid (Size)$1.65 (30)
Ask (Size)$1.71 (38)
Day Low / High$1.61 - 1.68
Volume630.0 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/18/2022

 

CytomX Therapeutics Inc ( NASDAQ )

Price: $1.65
Change: +0.02 (1.23%)
Volume: 630.0 K
4:00PM ET 8/18/2022
 
 

OncoCyte Corp ( NASDAQ )

Price: $0.92
Change: +0.05 (5.27%)
Volume: 178.6 K
4:00PM ET 8/18/2022
 
 

aTyr Pharma Inc ( NASDAQ )

Price: $3.98
Change: +0.01 (0.25%)
Volume: 65.3 K
4:00PM ET 8/18/2022
 
 

Assembly Biosciences Inc ( NASDAQ )

Price: $2.07
Change: -0.01 (0.48%)
Volume: 151.8 K
4:00PM ET 8/18/2022
 
 

Dare Bioscience Inc ( NASDAQ )

Price: $1.20
Change: +0.01 (0.84%)
Volume: 290.3 K
4:00PM ET 8/18/2022
 

Read more news Recent News

-- Earnings Flash (CTMX) CYTOMX THERAPEUTICS Posts Q2 Revenue $18.2M
4:19PM ET 8/04/2022 MT Newswires

...

CytomX Therapeutics to Cut Workforce by 40%, Extends Cash Runway into 2025
4:21PM ET 7/13/2022 MT Newswires

CytomX Therapeutics (CTMX) said Wednesday it is restructuring its business to prioritize internal investments in its emerging pre-clinical and early...

Cowen Downgrades CytomX Therapeutics to Market Perform From Outperform
8:51AM ET 7/11/2022 MT Newswires

CytomX Therapeutics (CTMX) has an average rating of outperform and price targets ranging from $1.50 to $8, according to analysts polled by Capital IQ. (MT...

HC Wainwright Downgrades CytomX Therapeutics to Neutral From Buy
6:14AM ET 7/11/2022 MT Newswires

CytomX Therapeutics (CTMX) has an average rating of outperform and price targets ranging from $1.50 to $11, according to analysts polled by Capital IQ. (MT...

Company Profile

Business DescriptionCytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA. View company web site for more details
Address151 Oyster Point Boulevard
South San Francisco, California 94080-1913
Phone+1.605.515.3185
Number of Employees137
Recent SEC Filing08/12/20224
Chairman, President & Chief Executive OfficerSean A. McCarthy
Chief Financial Officer & Senior Vice PresidentCarlos E. Campoy
Senior Vice President & Head-ResearchMarcia P. Belvin
Chief Medical Officer & Senior Vice PresidentAlison L. Hannah

Company Highlights

Price Open$1.64
Previous Close$1.65
52 Week Range$1.19 - 7.53
Market Capitalization$108.8 M
Shares Outstanding66.0 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.48
Beta vs. S&P 500N/A
Revenue$59.5 M
Net Profit Margin-133.42%
Return on Equity-121.88%

Analyst Ratings as of 07/08/2022

Buy
3
Overweight
1
Hold
6
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset